Stemtech Corp (STEK) stock
Close on Oct 19, 2026Market cap $207.74KP/E –Yield –
Stemtech Corp saw revenue fall 38.6% to $2.40M over the twelve months to Jun 30, 2026. Free cash flow was -$328.76K. At the latest close the market valued the company at $207.74K.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $207.74K
- P/E ratio
- –
- Price to sales
- 0.09
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -158.25%
Fundamentals
- Revenue
- $2.40M
- Net income
- -$3.84M
- EPS, diluted
- -$0.02
- Free cash flow
- -$328.76K
- Book value per share
- -$0.00
- Diluted shares
- 2.08B
Trading
- Previous close
- $0.00
- Open
- $0.00
- Day's range
- $0.00 – $0.00
- Volume
- 300,000
- Average volume (20 days)
- 4,408,411
Market cap history
Month-end market cap since 2021, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Oct 19, 2026. The S&P 500 is measured by the SPY fund.
| Period | STEK | S&P 500 | Difference | STEK per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | 0.0% | +0.6% | −0.6 pts | ||
| 3 months | 0.0% | +3.4% | −3.4 pts | ||
| Year to date | -87.5% | +13.3% | −100.8 pts | ||
| 1 year | -98.0% | +16.6% | −114.6 pts | ||
| 3 years | -99.7% | +86.4% | −186.1 pts | -86.0% | +23.1% |
Fifteen years at a glance
Fiscal years 2010 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Stemtech filed with the SEC as exhibits to Form 8-K or 6-K
About Stemtech
Wholesale-Drugs, Proprietaries & Druggists' Sundries
Stemtech Corporation is a network marketing company that develops and markets dietary supplements and skincare products designed to support adult stem cell physiology and wellness. Its supplement offerings, such as the RCM System, stemrelease3, StemFlo, MigraStem, and pet supplements, utilize plant-based botanicals formulated to assist the release, circulation, and tissue migration of adult stem cells. The company also produces oral healthcare items, including OraStem toothpaste, alongside topical skincare treatments like Cellect One Rapid Renew Night Cream and Cellect One Shield mist. Products reach consumers globally through independent business partners and direct-to-consumer distribution channels.
Company profile, executives and historyStemtech stock: common questions
What is Stemtech's stock price?
STEK closed at $0.00 on Oct 19, 2026, up 0.00% on the day.
What is Stemtech's market cap?
Stemtech was worth $207.74K at the close on Oct 19, 2026: the share price times the diluted shares outstanding.
What is STEK's P/E ratio?
Stemtech lost money over the twelve months to Jun 30, 2026 (diluted EPS -$0.02), so it has no meaningful P/E ratio.
How much revenue does Stemtech make?
Stemtech reported revenue of $2.40M for the twelve months to Jun 30, 2026, down 38.6% from a year earlier.
Does Stemtech pay a dividend?
No. Stemtech has not paid a cash dividend over the last twelve months.
How has STEK stock performed over the past year?
Including dividends, STEK returned -98.0% over the past year, against +16.6% for the S&P 500.
Who are Stemtech's competitors?
Companies most similar to Stemtech by business, industry and size include MEDS, VNOV, ESYN, HKPD, KOAN.
See a number that looks wrong?